Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2005

View Archived Issues

Comparative in vitro data of doripenem's potent antimicrobial activity / News in Context

Preclinical antidiabetic efficacy of MB-06322, a selective inhibitor of fructose 1,6-bisphosphatase

Muraglitazar improves glycemic control and lipid profile of patients with type 2 diabetes

Vantas not approvable in Canada

Bayer to study longer-acting Kogenate product in phase I

Hexvix NDA submission

Halozyme files IND for Chemophase

FDA agrees to file and review NDA for Fibrillex

Fampridine-SR enters phase III MS study

AVI submits IND for phase Ib study of AVI-4065 for HCV

Ariad opens enrollment for phase II endometrial cancer study of AP-23573

Phase III Crohn's disease study of Tysabri meets endpoints

Novel integrase inhibitors with different pharmacophores discovered

Agents for HIV infection in early development

Various agents for use in the treatment of cancer revealed in recent patents

Update on abatacept in rheumatoid arthritis

New phase I data on APD-125 in insomnia

Faster onset of action reported for AERx iDMS in type 1 diabetes

Temsirolimus shows promise in the treatment of multiple sclerosis

Procyon Biopharma completes acquisition of Bioxalis Medica

EMEA completes review of COX-2 inhibitors

Not approvable letter for tipifarnib

NitroMed launches BiDil

GenPat77 discovers novel protein that regulates immune cell activation

Recent patents described novel dermatologic compounds

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...